Chief Executive Officer, CatSci and Capital Drug Development

After completing his PhD in 2007, Ross joined AstraZeneca as a Senior Analytical Chemist to develop techniques to improve reaction understanding in process R&D. Ross’ analytical expertise and entrepreneurial mindset was pivotal to the establishment of CatSci in 2011. After four years in a number of leadership roles, in 2015, Ross became CEO with full P&L responsibility. He has since led the company’s transition from a catalyst screening company to the award-winning chemical process research and development CRO that it is today. CatSci has achieved a Compound Annual Growth Rate of ~ 68% over the last five years and has recently unveiled an ambitious three-year growth plan to become the preferred partner for process R&D of small molecule therapeutics. Headquartered in Cardiff, the company currently has a talented team of nearly 50 staff.


17 November 2020